Treatments involving immune checkpoint inhibitors (such as programmed death-1 (PD-1) inhibitor, programmed death-ligand 1 (PD-L1) inhibitor, and cytotoxic lymphocyte antigen 4 (CTLA4) inhibitor) are remarkably effective in many malignancies, including lung cancer. The gene discussed is CD274; the disease is lung cancer.